58 related articles for article (PubMed ID: 17402993)
1. Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
Diago M; Olveira A; Solá R; Romero-Gómez M; Moreno-Otero R; Pérez R; Salmerón J; Enríquez J; Planas R; Gavilán JC; Del Olmo J; Uribarrena R; Sillero C; Benítez A; Sánchez-Galdón S; Dalmau B; Eraña L; Montoro M; Portu J; Garijo JM; Barniol R; Domínguez A; Rota R; Olcoz JL; Antón M; Pamplona X; Casanovas T; Jiménez E; Huarte M; Díaz F; Sánchez-Ruano J; Orive M; Muñoz-Sánchez M; Roset M
Aliment Pharmacol Ther; 2007 Apr; 25(8):899-906. PubMed ID: 17402993
[TBL] [Abstract][Full Text] [Related]
2. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.
Lee SS; Bain VG; Peltekian K; Krajden M; Yoshida EM; Deschenes M; Heathcote J; Bailey RJ; Simonyi S; Sherman M;
Aliment Pharmacol Ther; 2006 Feb; 23(3):397-408. PubMed ID: 16422999
[TBL] [Abstract][Full Text] [Related]
3. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
Diago M; Crespo J; Olveira A; Pérez R; Bárcena R; Sánchez-Tapias JM; Muñoz-Sánchez M; Romero-Gómez M
Aliment Pharmacol Ther; 2007 Oct; 26(8):1131-8. PubMed ID: 17894655
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
7. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
8. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
[TBL] [Abstract][Full Text] [Related]
11. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
Ferenci P; Fried MW; Shiffman ML; Smith CI; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxì A; Chaneac M; Reddy KR
J Hepatol; 2005 Sep; 43(3):425-33. PubMed ID: 15990196
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.
Tang KH; Herrmann E; Pachiadakis I; Paulon E; Tatman N; Zeuzem S; Naoumov NV
Aliment Pharmacol Ther; 2008 May; 27(9):810-9. PubMed ID: 18221408
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
Borroni G; Andreoletti M; Casiraghi MA; Ceriani R; Guerzoni P; Omazzi B; Terreni N; Salerno F
Aliment Pharmacol Ther; 2008 May; 27(9):790-7. PubMed ID: 18298638
[TBL] [Abstract][Full Text] [Related]
14. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
15. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
Berg C; Goncales FL; Bernstein DE; Sette H; Rasenack J; Diago M; Jensen DM; Graham P; Cooksley G
J Viral Hepat; 2006 Jul; 13(7):435-40. PubMed ID: 16792536
[TBL] [Abstract][Full Text] [Related]
16. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis.
Kim AI; Dorn A; Bouajram R; Saab S
HIV Med; 2007 Jul; 8(5):312-21. PubMed ID: 17561878
[TBL] [Abstract][Full Text] [Related]
17. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
Moucari R; Ripault MP; Oulès V; Martinot-Peignoux M; Asselah T; Boyer N; El Ray A; Cazals-Hatem D; Vidaud D; Valla D; Bourlière M; Marcellin P
J Hepatol; 2007 Apr; 46(4):596-604. PubMed ID: 17218037
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
Fried MW; Hadziyannis SJ
Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
[TBL] [Abstract][Full Text] [Related]
19. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
Ciancio A; Picciotto A; Giordanino C; Smedile A; Tabone M; Manca A; Marenco G; Garbagnoli P; Andreoni M; Cariti G; Calleri G; Sartori M; Cusumano S; Grasso A; Rizzi R; Gallo M; Basso M; Anselmo M; Percario G; Ciccone G; Rizzetto M; Saracco G
Aliment Pharmacol Ther; 2006 Oct; 24(7):1079-86. PubMed ID: 16984502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
